Back

NovaGo Therapeutics raises $30 million Series B for spinal cord injury trial

Verifying
  • NovaGo Therapeutics completed a Series B financing to advance its acute spinal cord injury program.
  • The round totaled 24 million Swiss francs, or $30 million, led by Neurimmune and Pureos.
  • The proof-of-concept trial will enroll 120 patients across Germany, Spain and Switzerland.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.